Effectiveness of antitussives, anticholinergics or honey versus usual care in adults with uncomplicated acute bronchitis : a study protocol of an open randomised clinical trial in primary care
© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
INTRODUCTION: Despite the frequent use of therapies in acute bronchitis, the evidence of their benefit is lacking, since only a few clinical trials have been published, with low sample sizes, poor methodological quality and mainly in children. The objective of this study is to compare the effectiveness of three symptomatic therapies (dextromethorphan, ipratropium or honey) associated with usual care and the usual care in adults with acute bronchitis.
METHODS AND ANALYSIS: This will be a multicentre, pragmatic, parallel group, open randomised trial. Patients aged 18 or over with uncomplicated acute bronchitis, with cough for less than 3 weeks as the main symptom, scoring ≥4 in either daytime or nocturnal cough on a 7-point Likert scale, will be randomised to one of the following four groups: usual care, dextromethorphan 30 mg three times a day, ipratropium bromide inhaler 20 µg two puffs three times a day or honey 30 mg (a spoonful) three times a day, all taken for up to 14 days. The exclusion criteria will be pneumonia, criteria for hospital admission, pregnancy or lactation, concomitant pulmonary disease, associated significant comorbidity, allergy, intolerance or contraindication to any of the study drugs or admitted to a long-term residence.
SAMPLE: 668 patients. The primary outcome will be the number of days with moderate-to-severe cough. All patients will be given a paper-based symptom diary to be self-administered. A second visit will be scheduled at day 2 or 3 for assessing evolution, with two more visits at days 15 and 29 for clinical assessment, evaluation of adverse effects, re-attendance and complications. Patients still with symptoms at day 29 will be called 6 weeks after the baseline visit.
ETHICS AND DISSEMINATION: The study has been approved by the Ethical Board of IDIAP Jordi Gol (reference number: AC18/002). The findings of this trial will be disseminated through research conferences and peer-review journals.
TRIAL REGISTRATION NUMBER: NCT03738917; Pre-results.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
BMJ open - 9(2019), 5 vom: 16. Mai, Seite e028159 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cots, Josep M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.05.2020 Date Revised 18.05.2020 published: Electronic ClinicalTrials.gov: NCT03738917 Citation Status MEDLINE |
|---|
| doi: |
10.1136/bmjopen-2018-028159 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM297202596 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM297202596 | ||
| 003 | DE-627 | ||
| 005 | 20231226200152.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmjopen-2018-028159 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0990.xml |
| 035 | |a (DE-627)NLM297202596 | ||
| 035 | |a (NLM)31101700 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cots, Josep M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of antitussives, anticholinergics or honey versus usual care in adults with uncomplicated acute bronchitis |b a study protocol of an open randomised clinical trial in primary care |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.05.2020 | ||
| 500 | |a Date Revised 18.05.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03738917 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a INTRODUCTION: Despite the frequent use of therapies in acute bronchitis, the evidence of their benefit is lacking, since only a few clinical trials have been published, with low sample sizes, poor methodological quality and mainly in children. The objective of this study is to compare the effectiveness of three symptomatic therapies (dextromethorphan, ipratropium or honey) associated with usual care and the usual care in adults with acute bronchitis | ||
| 520 | |a METHODS AND ANALYSIS: This will be a multicentre, pragmatic, parallel group, open randomised trial. Patients aged 18 or over with uncomplicated acute bronchitis, with cough for less than 3 weeks as the main symptom, scoring ≥4 in either daytime or nocturnal cough on a 7-point Likert scale, will be randomised to one of the following four groups: usual care, dextromethorphan 30 mg three times a day, ipratropium bromide inhaler 20 µg two puffs three times a day or honey 30 mg (a spoonful) three times a day, all taken for up to 14 days. The exclusion criteria will be pneumonia, criteria for hospital admission, pregnancy or lactation, concomitant pulmonary disease, associated significant comorbidity, allergy, intolerance or contraindication to any of the study drugs or admitted to a long-term residence | ||
| 520 | |a SAMPLE: 668 patients. The primary outcome will be the number of days with moderate-to-severe cough. All patients will be given a paper-based symptom diary to be self-administered. A second visit will be scheduled at day 2 or 3 for assessing evolution, with two more visits at days 15 and 29 for clinical assessment, evaluation of adverse effects, re-attendance and complications. Patients still with symptoms at day 29 will be called 6 weeks after the baseline visit | ||
| 520 | |a ETHICS AND DISSEMINATION: The study has been approved by the Ethical Board of IDIAP Jordi Gol (reference number: AC18/002). The findings of this trial will be disseminated through research conferences and peer-review journals | ||
| 520 | |a TRIAL REGISTRATION NUMBER: NCT03738917; Pre-results | ||
| 650 | 4 | |a Clinical Trial, Phase IV | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a infectious diseases | |
| 650 | 4 | |a respiratory infections | |
| 650 | 4 | |a therapeutics | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Antitussive Agents |2 NLM | |
| 650 | 7 | |a Cholinergic Antagonists |2 NLM | |
| 650 | 7 | |a Dextromethorphan |2 NLM | |
| 650 | 7 | |a 7355X3ROTS |2 NLM | |
| 650 | 7 | |a Ipratropium |2 NLM | |
| 650 | 7 | |a GR88G0I6UL |2 NLM | |
| 700 | 1 | |a Moragas, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a García-Sangenís, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Morros, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Gomez-Lumbreras, Ainhoa |e verfasserin |4 aut | |
| 700 | 1 | |a Ouchi, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Monfà, Ramon |e verfasserin |4 aut | |
| 700 | 1 | |a Pera, Helena |e verfasserin |4 aut | |
| 700 | 1 | |a Pujol, Jesus |e verfasserin |4 aut | |
| 700 | 1 | |a Bayona, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a de la Poza-Abad, Mariam |e verfasserin |4 aut | |
| 700 | 1 | |a Llor, Carl |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ open |d 2012 |g 9(2019), 5 vom: 16. Mai, Seite e028159 |w (DE-627)NLM215724372 |x 2044-6055 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2019 |g number:5 |g day:16 |g month:05 |g pages:e028159 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmjopen-2018-028159 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2019 |e 5 |b 16 |c 05 |h e028159 | ||